Sure.
start times. let’s listening BioNTech, obviously, you all with that always at everyone’s So anticipate and
partners. So the with the is our -- negotiate phone not do what I’m to going over
far in delivery lipid these out at a space, as there context our of the other in sort in nanoparticle have of And two, obviously could imagine. of parties, that the because a none lot it a number facilitates what typically us, deals. technology IP, competition delivery the of from something So, number I’ll you technologies of has. is came way we see the of platform in else day, technical to confusion And these in nobody perspective, And as one. positions end BioNTech the the framing put ever
lock messenger exclusively that and our change can competition does relationship field. that number for your up out this an amount way different wrap to that a desire and oral an allows going is a sort messenger response, a not of dosing in immune So the from chain, now for potential in the entire cold generate completely of sensitivity technology RNA on sort delivery an repeat to that’s one. bit little competitive What RNA of is, of space the makes
the to biggest based their it’s get Bert, biggest you’ll which in opportunity, licensed arrangements, this challenge candidates. the see is know, think, or area. as for the typically arms parties targets product around think, you I upon you what I see also As are
We’re early side proof-of-concept. that preclinical that to of something that’s desire BioNTech. because doing value on But is BioNTech the for interest early for And a or advantage with at is little how and that, we’re The to challenge what most careful large competitive you maintain research is stage, that. us to key of be be. even opportunity just an this have real anticipate how could you
And level so signing of you design the that for the sense, and magic where formula a But comfortable, become and the some number term. of spirit different product scenarios what the makes that ultimately would to up the and candidates find today where take try the really parties into important. they’re discussions both account discussions exclusivity, and in both feel that’s longer you of
see over in being named past. be have you a as an want unique last dialogue and company want years you to the we’ve years, three companies, what open the delivery some to precedent. attributed the and technology delivery, able emerging between to levels, and approaching what’s smaller by you And highest of so you and or and the have the deals want big value differentiated that’s smaller who’s those happened at importance is think two a visibility of And companies larger you want to pharma, to supported is to I and deals have be
BioNTech acids. of in RNA delay, we go the want of obviously have We right not of technology, looks time mean, like, the -- advantages precedents obligation and But the have a is to for deal side. have through the while future deal, There’s on already having want fiduciary messenger want the want that we our don’t the one we the of an our the our other ongoing no deal, nucleic platform figure think stopping. advancing right there. we the shareholders. to delivery terms and is science parties right what I the we And out that. relationship I So with
opportunity is as to it’s as going ourselves a a maximize we that done where to and to create participate deal in putting and BioNTech way about candidates we able in can. product confident the We’re get can incent downstream position really many be
you advance messenger So meaningful they participation that do of RNA. field a to the an have as have commercial opportunity
I don’t we can more So so -- today. that I of know have a say that, where than sense urgency, but
As an we advanced are point near-term and we in the when our in appreciate. at hopefully, to stage, have get we a market that release, hopefully meaningful mentioned here can something press and the digest discussions the
